What this means
Researchers plan to measure muscle loss in patients with serious illness using ultrasound and blood markers. This is a trial that is recruiting, so no results are available yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over
- Where
- 1 site
The science
- Registered title
- Influence of Sarcopenia on the Course of the Diseases
- Trial ID
- NCT06829290 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Liver Cirrhosis, Cancer, Cachexia, Sarcopenia, Mechanical Ventilation
- What is tested
- Ultrasound
- Sponsor
- Universitatsmedizin Mainz - 1. Medizinische Klinik
- Ages
- 18 Years to no maximum
- Dates
- First posted Feb 17, 2025 · updated Feb 17, 2025
Registry summary
Frailty is a geriatric syndrome that primarily affects older patients, but also patients with severe illnesses. It is particularly common among oncology patients, but also among patients with gastrointestinal diseases such as liver cirrhosis or pancreatitis. Sarcopenia, a form of frailty, is defined as a loss of muscle quantity, quality and function. Currently, complex methods such as CT or bioimpedance measurement are available. However, simpler techniques such as ultrasound-based measurement could be alternatives, but still require further validation. In addition, serological muscle markers could support and simplify diagnostics.
The aim of this project is to be able to estimate the prognosis of patients at an early stage by measuring sarcopenia using ultrasound and biomarkers.
Sites (1)
- Universitatsmedizin Mainz, Mainz, Rhineland-Palatinate, Germany